An ultra-small bispecific protein augments tumor penetration and treatment for pancreatic cancer.
Purpose: The once highly anticipated antibody-based pathway-targeted therapies have not achieved promising outcomes for deadly pancreatic ductal adenocarcinoma (PDAC), mainly due to drugs' low intrinsic anticancer activity and poor penetration across the dense physiological barrier. This study aims...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 50; no. 6; pp. 1765 - 1780 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
May2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |